Both GRPR and its specific ligand GRP (gastrin-releasing peptide), are known to be overexpressed in several human malignancies, including neuroblastoma, lung, breast, pancreatic, colorectal, gastric, esophageal and prostatic cancer [11]. This evidence concerns the gene GRP and Familial prostate cancer.